**TITLE:**

Isolation of Myeloid-derived Suppressor Cells from Mouse Tumor and Determining Their Migration Potential *In Vitro*

**AUTHOR & AFFILIATION:**

Sharmistha Sarkar

Department of Genomic Medicine, UT MD Anderson Cancer Center, Houston, TX, 77054, USA

**CORRESPONDING AUTHOR:**

Sharmistha Sarkar

Email Address: ssarkar2@mdanderson.org

Tel: 713-792-6812

**KEYWORDS:**

MDSC isolation, migration assay, tumor dissociation, flow cytometry, murine, *in vitro*

**SHORT ABSTRACT:**

This article outlines the procedures to isolate myeloid-derived suppressor cells from mouse solid tumors and perform an *in vitro* assay with the cells to determine their response migration potential to certain soluble factors like cytokines and chemokines.

**LONG ABSTRACT:**

The importance of the immune response in cancer and other diseases (like diabetes mellitus, alzheimers, cystic fibrosis) is now known, and the manipulation of the immune system as a therapy to treat cancer is gaining attention. The immune system regulates tumorigenesis both negatively and positively. The myeloid-derived suppressor cells (MDSCs) are a population of immune cells that are increased during cancer, inflammation, and infection. These cells influence the immune response and effectively suppresses the anti-tumor T cell response. They serve as potential targets for therapeutic intervention to effectively use the immune system to inhibit tumorigenesis. To better understand how such intervention can be applied it is important to study these cell types. Using mouse ovarian tumors, we describe the isolation of MDSCs from solid tissue using gentle dissociation techniques. We further describe how MDSCs are isolated from such dissociated tissue based on the expression of cell surface markers with the help of flow cytometry. Additionally, we describe the procedure to perform an *in vitro* MDSC migration assay to determine the migration potential of these cells in response to soluble factors like cytokines and chemokines.

**INTRODUCTION:**

In recent years a number of studies have focused on understanding the role of immune cells in cancer development and progression. One way by which tumor cells evade the immune system is through the expression of immunosuppressive factors that activate, upregulate, and attract immune suppressive cells like MDSCs in the tumor microenvironment1.

MDSCs are a population of immature myeloid cells that are generated in the bone marrow. Under normal conditions, these immature cells differentiate into mature myeloid cells like macrophages, monocytes, or dendritic cells2. Under pathologic condition, these cells fail to differentiate completely into mature myeloid cells. Instead, they are expanded and activated by factors secreted by activated T cells, tumor cells, and stromal cells. Secretory proteins like stem-cell factor3, IL-6, granulocyte/macrophage CSF (G-CSF;M-CSF)4, vascular endothelial growth factor5, IFNγ6, ligands for Toll-like receptors (TLRs)7, IL-48, IL-139, and transforming growth factor β (TGFβ)10 promote MDSC proliferation and activation. Upon activation, these cells upregulate expression of factors like arginase 111, inducible nitric oxide synthase12, and reactive oxygen species13-17, resulting in their remarkable potential to suppress the T-cell response. In addition to inhibiting the adaptive immune response, MDSCs have been reported to negatively influence the innate immune response through macrophages18 and NK cells19.

These cells lack markers of mature myeloid cells. In mice, MDSCs are characterized by the expression of the cell surface markers GR1 and CD11b. Based on morphology, they are further characterized as granulocytic (CD11b+LY6G+LY6Clow) or monocytic (CD11b+LY6G−LY6Chi) MDSCs. Both subtypes have immunosuppressive properties, but in mouse tumors, the granulocytic MDSCs are the major population17. In humans, MDSC markers are not well characterized. Often, the monocytic MDSCs are identified as CD11b+ CD14+ CD33+high HLA-DRneg/Low and CD66bneg, while granulocytic MDSCs are identified as CD11b+ CD14neg CD33+low HLA-DRneg CD66b.

A number of functional studies in mouse tumor models have established the importance of MDSCs in tumor development and T cell suppression. Hence, they are potential targets for therapeutic intervention and it is critical to study this subset of immune cells to understand immune suppression in cancer. We need to identify new factors that may promote or inhibit MDSC expansion and activation, which can be utilized for therapy. To perform such tests, we need to isolate MDSCs in a simple and timely manner to obtain live, non-contaminated cells. Here, we outline the methods to isolate a viable MDSC population from mouse tumor. This method can be used to isolate MDSC from any other tissue following the same method. Cell types other than MDSCs can also be isolated by this method using the appropriate cell-specific markers. We also outline methods to determine MDSC migration potential towards a cytokine gradient. Here we use tumor necrosis factor α (TNFα) as an example. Other cytokines can also be tested. Instead of conditioned media from cell lines, regular media supplemented with specific cytokines in varying concentrations can be used to test the role of those cytokines in MDSC migration from a particular tumor type.

**PROTOCOL:**

All procedures were performed under the guidance of University of Texas at MD Anderson IACUC review board.

**1. Reagent Preparation**

**1.1 Preparation of medium for migration assay**

* 1. Prepare 500 mL of complete RPMI media for the migration assay: RPMI medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% pen-strep (penicillin 500 U/mL and streptomycin 500 µg/mL).

**1.2 Preparation of buffers for staining MDSCs**

1.2.1. Prepare the tumor dissociation buffer with 100 U/mL Collagenase type IV and 100 μg/mL DNase in RPMI with 10% FBS. Store the buffer on ice.

1.2.2. Prepare the 1X RBC lysis buffer by diluting the 10X stock 1:10 in sterile water.

1.2.3. Prepare the FACS buffer by adding 1% heat-inactivated FBS to 1X PBS.

1.2.4. Add 1 µL of amine reactive viability dye (binds and fluoresces non-viable or necrotic cells more strongly than live cells) to 1 mL of FACS buffer to stain for dead cells. Store the solution in the dark on ice or at 4 °C.

1.2.5. Prepare the staining buffer by adding 20 µL each of the following antibodies (α-FITC-GR1, α-BV510-CD11b, α-APC-Cy7-CD45, α-PE-Cy7-Ly6C, and α-APC-Ly6G) in 940 mL of FACS buffer with cell viability dye. Keep the antibody cocktail covered on ice or 4 °C.

**1.3 Generation of murine tumors**

Note: When syngeneic mice are injected with a murine ovarian cancer cell line 333 derived from TPP20 mice, they will spontaneously form tumors 8–12 weeks post injection. These cells can be modified to stably express PRKCI by lentiviral infection21.

1.3.1. Grow 333 cells in DMEM with glutamine supplementation on 15 cm tissue culture plates in a tissue culture incubator at 37 °C and 5% CO2.

1.3.2. To passage the cells: aspirate the media, add 5 mL of 2.5% trypsin with EDTA, and incubate for 1–2 min at 37 °C and 5% CO2. When the cells detach from the tissue culture plate, neutralize trypsin with 5 mL of DMEM and collect the cells in a 15 mL tube. Centrifuge the cells at 300 x g for 5 min at room temperature.

1.3.3. Discard the supernatant and resuspend the cell pellet in 10 mL of HBSS media. Count the cells using trypan blue (4%, 1:1 cell suspension to dye ratio) and a cell counter.

1.3.4. Aliquot the cell suspension according to cells required and concentration of cells. Inject intraperitoneally, 10 million cells per mice into 4–6 week old syngeneic BL/6 mice. Let the tumors grow for 8–12 weeks.

**2. Isolation of Single Cells from Tumor Tissue and Staining Cells for FACS**

2.1. When the mice develop tumors 8–12 weeks post injection (determined by bloated abdomen cavity), euthanize the mice by CO2 asphyxiation.

2.2. Pin down all four limbs of a mouse on a polystyrene foam board with the abdominal cavity facing up. Cut open the abdominal cavity using sharp scissors and expose the tumor tissue. If the tissue is isolated from a large tumor, avoid using the center mass of the tumor if it appears necrotic.

2.3. Aseptically collect the freshly dissected murine intraperitoneal tumor from the mice in a 50 mL tube with 2.5 mL/g of tumor dissociation buffer to tissue.

Note: This protocol can be used for subcutaneous xenograft tumors or for the isolation of single cells from most mouse tissue. The percentage of MDSCs in tumors varies and needs to be determined for the specific tumor type. To collect enough MDSCs from the isolation, multiple tumor samples from the same experimental background can be combined.

2.4. In a tissue culture hood, transfer the tissue to a culture dish with a small amount of tumor and dissociation buffer and chop the tumor with a razor blade into smaller pieces, about 2 mm in size.

2.5. Transfer the chopped tissue back into the tube and incubate the partially dissociated tissue at 37 °C with continuous rotation on a rotator at approximately 12 rpm for 45 min.

2.6. After incubation, centrifuge the dissociated tissue in the tube at 300 x g for 5 min at room temperature. Discard the supernatant.

2.7. Resuspend the dissociated tissue in 25 mL of RPMI and filter through a 70-µm cell strainer placed on a 50 mL tube to collect single cells from the dissociated tissue.

2.8. Centrifuge the single cell suspension at 300 x g for 5 min at room temperature and discard the supernatant.

2.9. Add 25 mL of 1X RBC lysis buffer to the tube and incubate on ice for 5 min to lyse RBCs in the cell suspension.

2.10. Centrifuge the cells at 300 x g for 5 min at room temperature and discard the red supernatant. If the cell pellet still appears red or dark brown, repeat the RBC lysis step (step 2.9).

2.11. Add 25 mL of PBS to the cell pellet and centrifuge at 300 x g for 5 min at room temperature. Discard the supernatant.

2.12. Resuspend the isolated single cells in 1 mL of FACS buffer and proceed to stain the immune cells.

**3. Staining and Isolation of MDSCs from Single Cells Isolated from Mouse Tumor**

3.1. Aspirate two 50 µL aliquots of the single cell suspension into centrifuge tubes for the controls. To one tube, add 100 µL of FACS buffer. To the other tube, add 100 µL FACS buffer containing cell viability dye (see step 1.2.4). Keep the controls on ice until use.

3.2. Centrifuge the remaining cell suspension at 300 x g for 5 min and then incubate the cell pellet with FACS staining buffer (see step 1.2.5) containing anti-CD45 (4 µg/mL), anti-Gr1 (10 µg/mL), anti-Cd11b (4 µg/mL), anti-Ly6C (4 µg/mL), and anti-Ly6G (4 µg/mL) antibodies.

3.2.1. Incubate the cell suspension with the antibody solution on ice in the dark for 30 min.

3.2.2. Centrifuge the antibody conjugated cells at 300 x g for 5 min at 4 °C and discard the supernatant. Keep the tubes covered with aluminum foil to avoid light exposure.

3.2.3. Resuspend the cells in FACS buffer, count them using a cell counter, centrifuge the cells at 300 x g for 5 min at 4 °C, and discard the supernatant. Repeat this step once more and discard the supernatant.

3.2.4. Resuspend the stained cells in 1 mL of FACS buffer and keep on ice covered with aluminum foil before FACS.

3.3. For the color compensation controls for flow cytometry, take 100 µL of compensation beads in a centrifuge tube and add 1 mL of FACS buffer. Centrifuge the beads at 300 x g for 5 min and discard the supernatant.

3.3.1. Resuspend the beads in 150 µL of FACS buffer and divide them equally into three parts (50 µL/tube). To each part, add anti-FITC-GR1 (1.6 µg/mL), anti-BV510-CD11b (0.6 µg/mL), and anti-APC-Cy7-CD45 (0.6 µg/mL) for the staining. Incubate for 15 min on ice in the dark.

3.3.2. Centrifuge the beads at 300 x g for 5 min and discard the supernatant.

3.3.3. Add 1 mL of FACS buffer and centrifuge the beads at 300 x g for 5 min. Discard the supernatant.

3.3.4. Resuspend the beads in 500 µL of FACS buffer and store on ice before flow cytometry and cell sorting.

**4. Flow cytometry and Cell Sorting of the MDSCs from Mouse Tumor**

Note: See **Figure 1**. Here, we performed flow cytometry and cell sorting in a core facility.

4.1. Sort the stained MDSCs using fluorescence-activated cell sorting (FACS). For color compensation, use the compensation beads stained with individual antibodies (step 3.3). Use the cells stained with only the viability dye for the compensation of dead and live cells (step 3.1).

4.2. Use the unstained cells (step 3.1) as a negative control before running the stained samples.

4.3. For sorting the samples, gate on the total events based on forward and side scatter of the density plots to remove all doublets and cellular debris.

4.4. Exclude all dead cells based on the positive viability dye staining.

4.5. Gate on live single cells positive for CD45 staining (total leukocytes), followed by cells double positive for CD11b+ and Gr1+ to collect MDSCs. CD11b+/Gr1+ MDSCs can be further gated for monocytic and granulocytic markers with Ly6C and Ly6G as shown in **Figure 1**. For the purpose of the MDSC migration assay, CD11b+/Gr1+ MDSCs are sufficient.

4.6. Sort the cells into a collection tube with complete RPMI media.

**5. MDSC Migration Assay**

5.1. Centrifuge the sorted MDSCs at 300 x g for 5 min at room temperature. Discard the supernatant.

5.2. Resuspend the cell pellet with 10 mL of RPMI media with pen-strep and without FBS. Centrifuge at 300 x g for 5 min at room temperature and discard the supernatant. Repeat this step once.

5.3. Prepare a cell suspension of the sorted cells at 0.3–0.5 x 106 cells per 0.5 mL of RPMI media with pen-strep and without FBS.

5.4. Count the cells using trypan blue (4%, 1:1 cell suspension to dye ratio) and a cell counter.

5.5. Add 500 mL/well of complete RPMI media (with pen-strep and FBS; see step 1.1) of a 24-well plate. Add desired concentrations of the cytokine to be tested. As a control, add neutralizing antibody corresponding to the cytokine tested as one set of conditions. Replicate each condition in at least 3 wells.

5.6. Gently place a membrane-insert into each well to avoid the formation of any bubbles under the membrane.

5.7. Add 500 mL of cell suspension containing 0.3–0.5 x106 sorted MDSCs into each membrane insert and incubate the plate for 6 h at 37 °C, 5% CO2 in a tissue culture incubator.

5.8. Count the migrated MDSCs in the bottom chamber of the transwell system by counting the absolute number of FITC positive cells using flow cytometry.

**REPRESENTATIVE RESULTS:**

Here, we present results obtained from the isolation of MDSCs from mouse ovarian tumors20. Following the procedure described above, we isolated single cells and stained them for MDSCs. MDSCs in the tumors were labeled with APC-Cy7-CD45, FITC-GR1, PE-CD11b. To elucidate the MDSC population, these cells can be further stained with Ly6C and Ly6G, as shown in the gating strategy in **Figure 1**. Labeled cells were sorted by flow cytometry. Labeled cells were first gated for total events based on the forward and side scatter of the density plots to remove all doublets and cellular debris. All dead cells were excluded based on viability dye staining. Live cells were then gated for CD45 staining for total leukocytes, followed by CD11b+Gr1+ double positive cells to isolate MDSCs (**Figure 1**). In our tumors, we obtained a yield of about 45% MDSCs in the total CD45 population. Further gating of CD11b+Gr1+ for Ly6G and Ly6C gives the granulocytic and monocytic populations, respectively. For the purpose of the MDSC migration assay, CD11b+Gr1+ double positive cells were used irrespective of their granulocytic or monocytic nature. All fluorophores were compensated using compensation beads, and dead cell compensation was performed with a cell sample that was stained with cell viability dye. Statistical significance was tested using Student’s *t*-test.

We have shown in previous work that the MDSCs from the ovarian tumors respond to TNFα20. Hence for our migration assay here we have used TNFα as the tested cytokine. Complete RPMI media was added to the wells of a 24-well plate. The different conditions were: 1) TNFα, and 2) TNFα + anti-TNFα neutralizing antibody to test if TNFα induced migration can be rescued by the neutralizing the antibody. Each condition of the experiment was performed in triplicate. MDSCs sorted by flow cytometry were washed with serum-free media and plated at 0.5 x 106 cells/well in serum-free media in the upper chamber of permeable membrane well inserts. For TNFα neutralization, complete RPMI media was pre-treated with TNFα and its neutralizing antibody. Cells were allowed to migrate to the bottom of the well for 6 h at 37 °C, 5% CO2. Migrated cells were then analyzed by flow cytometry. Migrated FITC positive cells were gated to count the absolute number of cells migrated through the membrane insert. **Figure 2** shows the increased migration of MDSCs in media with TNFα compared to untreated media; this suggests that TNFα promotes migration of these MDSCs isolated from mouse tumors. Neutralization of TNFα by antibody reduced the MDSC migration.

**FIGURE LEGENDS:**

**Figure 1. Gating strategy for sorting CD45+GR1+CD11b+ myeloid-derived suppressor cells.** First, single cells are gated and then live cells that lack viability dye stain are gated. Following that, CD45+ cells are gated from the live cells. Once CD45+ cells are identified, Gr1+ and Cd11b+ cells are gated for MDSCs. These cells have been used for the MDSC migration assay. Further gating of MDSCs can be performed for granulocytic and monocytic MDSCs using Ly6G and Ly6C markers as shown in this figure.

**Figure 2. Migration of MDSCs.** MDSC isolated from ovarian tumors show increased migration with complete RPMI media with TNFα. The increased migration is partially rescued by pretreating media with TNFα and its neutralizing antibody. The *p* value in each case is represented by “\*”. (\*\*= 0.0026, \*\*\*\*= <0.0001). The experiment was performed in triplicate for each condition.

**DISCUSSION:**

We have described the methodology to isolate MDSCs from mouse ovarian tumor. The same method can be utilized for isolating MDSCs or other immune cells from any solid normal tissue or solid tumor using cell-specific markers. Additionally, depending on the nature of the tissue the incubation time with the dissociation buffer will need to be optimized.

The isolation of viable immune cells from tumor tissue depends on performing the different isolation steps from dissecting tumors to obtain the sorted MDSCs in a timely manner. Extended incubations in digestion buffer can lead to more cell death. It is also critical to maintain aseptic conditions to avoid contamination of the cells.

While performing the migration assay setup, it is critical to ensure that no bubbles are created below the membrane insert chamber as that will inhibit migration and produce erroneous results. Finally, we have used TNFα as an example cytokine for the assay. Other cytokines like IL-6, IL-1A, and IL-1B can also be tested. Instead of regular media, conditioned media from cell lines can also be used to test whether the cells secrete any soluble factor that promotes MDSC migration from a particular tumor type. Finally, this method of MDSC isolation can also be used for further *in vitro* assays like the T cell proliferation assay20. One limitation of this method is it is tedious when there are a large number of samples as each step needs to be performed within an optimal time limit. Prolonged steps may affect the quality of the cells and the data obtained.

**DISCLOSURES**

The authors declare that they have no competing financial interests.

**ACKNOWLEDGMENTS**

This work was supported by the Ann and Sol Schreiber Mentored Investigator Award (POE/DF/02.2011) awarded to SS.

**REFERENCES**

1 Sevko, A. & Umansky, V. Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. *J Cancer.* **4** (1), 3-11, (2013).

2 Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. *Nat Rev Immunol.* **12** (4), 253-268, (2012).

3 Pan, *P*. Y. *et al.* Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. *Blood.* **111** (1), 219-228, (2008).

4 Serafini, *P*. *et al.* High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. *Cancer Res.* **64** (17), 6337-6343, (2004).

5 Gabrilovich, D. *et al.* Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages *in vivo*. *Blood.* **92** (11), 4150-4166, (1998).

6 Movahedi, K. *et al.* Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. *Blood.* **111** (8), 4233-4244, (2008).

7 Delano, M. J. *et al.* MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. *J Exp Med.* **204** (6), 1463-1474, (2007).

8 Bronte, V. *et al.* IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. *J Immunol.* **170** (1), 270-278, (2003).

9 Rutschman, R. *et al.* Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production. *J Immunol.* **166** (4), 2173-2177, (2001).

10 Terabe, M. *et al.* Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. *J Exp Med.* **198** (11), 1741-1752, (2003).

11 Rodriguez, *P*. C. & Ochoa, A. C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. *Immunol Rev.* **222** 180-191, (2008).

12 Bingisser, R. M., Tilbrook, *P*. A., Holt, *P*. G. & Kees, U. R. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. *J Immunol.* **160** (12), 5729-5734, (1998).

13 Kusmartsev, S., Nefedova, Y., Yoder, D. & Gabrilovich, D. I. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. *J Immunol.* **172** (2), 989-999, (2004).

14 Waris, G. & Ahsan, H. Reactive oxygen species: role in the development of cancer and various chronic conditions. *J Carcinog.* **5** 14, (2006).

15 Schmielau, J. & Finn, O. J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. *Cancer Res.* **61** (12), 4756-4760, (2001).

16 Szuster-Ciesielska, A., Hryciuk-Umer, E., Stepulak, A., Kupisz, K. & Kandefer-Szerszen, M. Reactive oxygen species production by blood neutrophils of patients with laryngeal carcinoma and antioxidative enzyme activity in their blood. *Acta Oncol.* **43** (3), 252-258, (2004).

17 Youn, J. I., Nagaraj, S., Collazo, M. & Gabrilovich, D. I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. *J Immunol.* **181** (8), 5791-5802, (2008).

18 Sinha, *P*., Clements, V. K., Bunt, S. K., Albelda, S. M. & Ostrand-Rosenberg, S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. *J Immunol.* **179** (2), 977-983, (2007).

19 Li, H., Han, Y., Guo, Q., Zhang, M. & Cao, X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. *J Immunol.* **182** (1), 240-249, (2009).

20 Sarkar, S. *et al.* PRKCI promotes immune suppression in ovarian cancer. *Genes Dev.* **31** (11), 1109-1121, (2017).

21 Cribbs, A. *P*., Kennedy, A., Gregory, B. & Brennan, F. M. Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells. *BMC Biotechnol.* **13** 98, (2013).